📊 BIOE Key Takeaways
Investment Thesis
Bio Essence Corp exhibits severe financial distress with negative stockholders' equity of -$3.1M and deteriorating operational performance including 41.3% YoY revenue decline. The company faces imminent solvency risk with current ratio of 0.06x, indicating critical liquidity constraints and inability to meet near-term obligations. While positive operating cash flow provides temporary relief, the underlying business fundamentals are deeply challenged with negative operating margins of -31.0% and minimal cash reserves.
BIOE Strengths
- Strong gross margin of 68.2% suggests viable product pricing
- Positive operating cash flow of $328.7K demonstrates some cash generation capability
- Free cash flow of $325.1K with 77.8% FCF margin shows non-cash charges may be inflating losses
BIOE Risks
- Negative stockholders' equity of -$3.1M indicates balance sheet insolvency and technical bankruptcy
- Severe liquidity crisis with current ratio of 0.06x and only $28.7K cash against $3.3M liabilities
- Revenue collapse of 41.3% YoY combined with negative operating margin of -31.0% signals business model failure
- Total liabilities of $3.3M exceed total assets of $184.5K by 17.9x, creating existential refinancing risk
- No insider support with zero Form 4 filings in last 90 days suggests management lack of confidence
Key Metrics to Watch
- Quarterly revenue trend and path to profitability
- Stockholders' equity trajectory and capital restructuring plans
- Operating cash flow sustainability and working capital management
- Debt refinancing status and covenant compliance
BIOE Financial Metrics
💡 AI Analyst Insight
The 77.8% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. The current ratio below 1.0x warrants monitoring of short-term liquidity.
BIOE Profitability Ratios
BIOE vs Healthcare Sector
How Bio Essence Corp compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
BIOE Balance Sheet & Liquidity
BIOE 5-Year Financial Trend
5-Year Trend Summary: Bio Essence Corp's revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.03 indicates the company is currently unprofitable.
BIOE Growth Metrics (YoY)
BIOE Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $134.7K | $13.0K | N/A |
| Q2 2025 | $41.7K | $59.9K | $0.00 |
| Q1 2025 | $22.2K | $133.9K | $0.00 |
| Q3 2024 | $134.7K | $133.9K | $-0.01 |
| Q3 2023 | $155.7K | -$164.2K | $-0.01 |
| Q2 2023 | $259.6K | -$164.2K | $0.00 |
| Q1 2023 | $306.4K | -$178.8K | $-0.01 |
| Q3 2022 | $192.1K | -$163.5K | $-0.01 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
BIOE Capital Allocation
BIOE SEC Filings
Access official SEC EDGAR filings for Bio Essence Corp (CIK: 0001723059)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BIOE
What is the AI rating for BIOE?
Bio Essence Corp (BIOE) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are BIOE's key strengths?
Strong gross margin of 68.2% suggests viable product pricing. Positive operating cash flow of $328.7K demonstrates some cash generation capability.
What are the risks of investing in BIOE?
Negative stockholders' equity of -$3.1M indicates balance sheet insolvency and technical bankruptcy. Severe liquidity crisis with current ratio of 0.06x and only $28.7K cash against $3.3M liabilities.
What is BIOE's revenue and growth?
Bio Essence Corp reported revenue of $418.1K.
Does BIOE pay dividends?
Bio Essence Corp does not currently pay dividends.
Where can I find BIOE SEC filings?
Official SEC filings for Bio Essence Corp (CIK: 0001723059) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BIOE's EPS?
Bio Essence Corp has a diluted EPS of $0.00.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.